UK markets closed
  • NIKKEI 225

    29,620.99
    +82.29 (+0.28%)
     
  • HANG SENG

    28,900.83
    +403.58 (+1.42%)
     
  • CRUDE OIL

    63.35
    +3.17 (+5.27%)
     
  • GOLD FUTURES

    1,735.70
    -11.90 (-0.68%)
     
  • DOW

    33,855.79
    +178.52 (+0.53%)
     
  • BTC-GBP

    46,284.71
    +164.50 (+0.36%)
     
  • CMC Crypto 200

    1,380.25
    +4.48 (+0.33%)
     
  • ^IXIC

    13,945.02
    -51.07 (-0.36%)
     
  • ^FTAS

    3,964.67
    +25.36 (+0.64%)
     

ContextVision presents Annual Report 2020

ContextVision AB
·1-min read

STOCKHOLM – April 7, 2021 – Please find ContextVision’s Annual Report 2020 and Remuneration Report 2020 attached. The reports can also be found on the company’s website: www.contextvision.se

Printed copies of the reports will be distributed upon request by e-mail: finance@contextvision.se

For inquiries, please contact CFO Ann-Charlotte Linderoth
E-mail: ann-charlotte.linderoth@contextvision.se

###

About ContextVision

ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world.

Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment.

ContextVision is now entering the fast-growing digital pathology market. We are re-investing significantly in our product portfolio of decision support tools and we are dedicated to becoming a leading resource for pathologists to radically develop cancer diagnosis and improve patient care.

The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.


This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachments